2006 Meeting Preliminary Plenary Program
|
Mon. Feb. 6
|
Tue. Feb. 7
|
Wed. Feb. 8
|
Thu. Feb. 9
|
|
|---|---|---|---|---|
|
AM
|
Oncogenic Pathways
|
Cancer-relevant cofactors
|
Oncogenic manifestations
|
Evidence-based interventions
|
|
1.
|
Cyclin-dependent kinases - CDKs - in cell cycle control
|
Alcohol dehydrogenase genotypes & head / neck cancer
|
Abnormal mitotic segregation of chromosomes
|
CDK inhibitors
|
|
2.
|
Fusion genes & rearranged genes as a linear function of chromosome aberrations
|
Environmental exposures
|
Defect of checkpoint kinase 2 (ChK2) activity
|
Promises & perils of new paradigms in cervical cancer
|
|
3.
|
Genetic polymorphisms & cancer risks
|
Molecular pathogenesis of lung cancer in smokers & never smokers
|
Hypermethylation - multiple genes in adjacent normal-appearing tissues
|
Histone deacetylase HDACs inhibitors
|
|
4.
|
RNAi
|
Epigenetic changes in human carcinogenesis
|
Chromatin aberrations in normal-appearing PBL
|
Induction of apoptosis
|
|
5.
|
Sonic hedgehog signaling pathways
|
Chronic inflammation
|
Predictive changes of susceptibility
|
Anti-angiogenesis therapy & prevention
|
|
6.
|
Cooperative interactions in transformation
|
Diet & physical inactivity
|
Skin manifestations of cancer
|
Stem cell biology
|
|
PM
|
Risk identification
|
Predictive biomarkers
|
Precursor lesions and management
|
Novel immunological interventions
|
|
1.
|
Biologic indicators of genotoxic exposure
|
Molecular imaging
|
Esophago-gastric mucosa
|
Interferon consensus sequence-binding protein (ICSBP) & tumor escape
|
|
2.
|
Gene-environmental interaction: what have we learned?
|
CIN P161 NK4a positive cells as a prognostic biomarker
|
Hereditary non-polyposis coli
|
Modified T-cells for lymphoma immunotherapy
|
|
3.
|
Identification of carcinogens: the IARC model
|
Genetic & proteomic markers of exposure & susceptibility
|
Pancreatitis: Genetic aspects
|
Cytosine phosphate guanidine (CPG) as vaccine adjuvant
|
|
4.
|
Early life-style events in cancer causation
|
Epigenetic biomarkers of development & progression
|
Benign breast disease & cancer risk
|
Intra-lesional vaccine administration
|
|
5.
|
Molecular precursors & preneoplastic lesions
|
Chromosome interchanges identified by multicolor banding in lymphocytes
|
Chromosomal aberrations & cancer risk
|
Gene transfer for immunotherapy
|
|
6.
|
Aberrant DNA methylation & chromatin modification
|
Protein biomarkers: early ovarian & pancreatic cancer
|
PIN, chronic inflammation in initiation & progression
|
Cancer vaccines
|